Evidence map›Paper›PMID 35589824›Full record

ArticleScientific reports2022

Predicting target-ligand interactions with graph convolutional networks for interpretable pharmaceutical discovery.

Paola Ruiz Puentes, Laura Rueda-Gensini, Natalia Valderrama, Isabela Hernández, Cristina González, Laura Daza, Carolina Muñoz-Camargo, Juan C Cruz, Pablo Arbeláez

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Paola Ruiz Puentes *Center for Research and Formation in Artificial Intelligence, Universidad de los Andes, Bogotá, 111711, Colombia.
Laura Rueda-Gensini *Center for Research and Formation in Artificial Intelligence, Universidad de los Andes, Bogotá, 111711, Colombia.
Natalia Valderrama *Center for Research and Formation in Artificial Intelligence, Universidad de los Andes, Bogotá, 111711, Colombia.
Isabela HernándezCenter for Research and Formation in Artificial Intelligence, Universidad de los Andes, Bogotá, 111711, Colombia.
Cristina GonzálezCenter for Research and Formation in Artificial Intelligence, Universidad de los Andes, Bogotá, 111711, Colombia.
Laura DazaCenter for Research and Formation in Artificial Intelligence, Universidad de los Andes, Bogotá, 111711, Colombia.
Carolina Muñoz-CamargoDepartment of Biomedical Engineering, Universidad de los Andes, Bogotá, 111711, Colombia.
Juan C CruzDepartment of Biomedical Engineering, Universidad de los Andes, Bogotá, 111711, Colombia.
Pablo ArbeláezCenter for Research and Formation in Artificial Intelligence, Universidad de los Andes, Bogotá, 111711, Colombia. pa.arbelaez@uniandes.edu.co.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug Discovery is an active research area that demands great investments and generates low returns due to its inherent complexity and great costs. To identify potential therapeutic candidates more effectively, we propose protein-ligand with adversarial augmentations network (PLA-Net), a deep learning-based approach to predict target-ligand interactions. PLA-Net consists of a two-module deep graph convolutional network that considers ligands' and targets' most relevant chemical information, successfully combining them to find their binding capability. Moreover, we generate adversarial data augmentations that preserve relevant biological backgrounds and improve the interpretability of our model, highlighting the relevant substructures of the ligands reported to interact with the protein targets. Our experiments demonstrate that the joint ligand-target information and the adversarial augmentations significantly increase the interaction prediction performance. PLA-Net achieves 86.52% in mean average precision for 102 target proteins with perfect performance for 30 of them, in a curated version of actives as decoys dataset. Lastly, we accurately predict pharmacologically-relevant molecules when screening the ligands of ChEMBL and drug repurposing Hub datasets with the perfect-scoring targets.

Indexed as

Neural Networks, ComputerProteinsLigandsPharmaceutical PreparationsPolyestersLigandsPharmaceutical PreparationsPolyestersProteins

Identifiers

PMID35589824
PMCPMC9119967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.